Skip to main content

Dr. Matthew C. Cave, M.D.

Gastroenterology (Gastroenterology Physician)

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2007
Medicare patients seen, 2024
124

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2001Medical school: University of Kentucky College of Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Gastroenterology Physician primary
    KY license 38459
  • Hepatology Physician
    KY license 38459
  • Internal Medicine Physician
    KY license 38459
  • Transplant Hepatology Physician
    KY license 38459

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Gastroenterology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
124
Services billed
267
Patients’ average age
69
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes9854
Established patient office or other outpatient visit, 30-39 minutes6851
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes3533
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes3428
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes2020
Established patient office or other outpatient visit, 20-29 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 89 payments worth $106,635 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$78,926
Speaking at a medical education program$12,400
Travel and Lodging$7,517
Consulting Fee$5,580
Food and Beverage$2,212

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 10, 2025Novo Nordisk Inc
Oct 10, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$11,127
Nov 6, 2025Novo Nordisk Inc
Nov 6, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$8,046
Oct 29, 2025Novo Nordisk Inc
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$7,654
Nov 13, 2025Novo Nordisk Inc
Nov 13, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$6,869
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Consulting Fee
OCALIVA · Hepatology / Gastroenterology
$5,580
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$5,288
Nov 19, 2025Novo Nordisk Inc
Nov 19, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$5,103
Dec 12, 2025Ipsen Biopharmaceuticals, Inc
Dec 12, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$5,049
Jul 15, 2025Intercept Pharmaceuticals, Inc.
Jul 15, 2025
Speaking at a medical education program
OCALIVA · Hepatology / Gastroenterology
$4,960
Oct 21, 2025Madrigal Pharmaceuticals
Oct 21, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
All 41 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 12, 2025Ipsen Biopharmaceuticals, Inc
Dec 12, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$5,049
Nov 19, 2025Novo Nordisk Inc
Nov 19, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$5,103
Nov 13, 2025Novo Nordisk Inc
Nov 13, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$6,869
Nov 13, 2025Novo Nordisk Inc
Nov 13, 2025
Travel and Lodging
Wegovy · Obesity · travel to Lexington, KY · in-kind
$56.22
Nov 6, 2025Novo Nordisk Inc
Nov 6, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$8,046
Nov 6, 2025Novo Nordisk Inc
Nov 6, 2025
Travel and Lodging
Wegovy · Obesity · travel to Bowling Green, KY · in-kind
$902
Oct 29, 2025Novo Nordisk Inc
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$7,654
Oct 29, 2025Novo Nordisk Inc
Oct 29, 2025
Travel and Lodging
Wegovy · Obesity · travel to Cincinnati, OH · in-kind
$800
Oct 21, 2025Madrigal Pharmaceuticals
Oct 21, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Oct 21, 2025Madrigal Pharmaceuticals
Oct 21, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to BLOOMINGTON, IN
$155
Oct 10, 2025Novo Nordisk Inc
Oct 10, 2025
Compensation for services other than consulting (speaking, faculty)
Wegovy · Obesity
$11,127
Oct 10, 2025Novo Nordisk Inc
Oct 10, 2025
Travel and Lodging
Wegovy · Obesity · travel to Atlanta, GA · in-kind
$568
Oct 10, 2025Novo Nordisk Inc
Oct 10, 2025
Travel and Lodging
Wegovy · Obesity · travel to Atlanta, GA · in-kind
$412
Oct 10, 2025Novo Nordisk Inc
Oct 10, 2025
Travel and Lodging
Wegovy · Obesity · travel to Atlanta, GA · in-kind
$221
Oct 10, 2025Novo Nordisk Inc
Oct 10, 2025
Travel and Lodging
Wegovy · Obesity · travel to Atlanta, GA · in-kind
$32.40
Sep 11, 2025Gilead Sciences, Inc.
Sep 11, 2025
Compensation for services other than consulting (speaking, faculty)
Livdelzi · INFLAM
Company’s description;4261151;AHM;10004544
$3,790
Aug 27, 2025Madrigal Pharmaceuticals
Aug 27, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Aug 4, 2025Madrigal Pharmaceuticals
Aug 4, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$5,288
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind
$492
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind
$244
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind
$232
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX
$40.00
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX
$32.79
Jul 15, 2025Intercept Pharmaceuticals, Inc.
Jul 15, 2025
Speaking at a medical education program
OCALIVA · Hepatology / Gastroenterology
$4,960
Jul 15, 2025Intercept Pharmaceuticals, Inc.
Jul 15, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Evansville, IN · in-kind
$1,173
May 30, 2025Gilead Sciences, Inc.
May 30, 2025
Compensation for services other than consulting (speaking, faculty)
Livdelzi · INFLAM
Company’s description;4116623;AHM;10004544
$3,790
May 15, 2025Gilead Sciences, Inc.
May 15, 2025
Compensation for services other than consulting (speaking, faculty)
Livdelzi · INFLAM
Company’s description;4120880;AHM;10004544
$4,930
May 14, 2025Gilead Sciences, Inc.
May 14, 2025
Travel and Lodging
Livdelzi · INFLAM · travel to Lexington, KY · in-kind
Company’s description;4327987;AHM;10004544
$737
May 13, 2025Ipsen Biopharmaceuticals, Inc
May 13, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$1,377
May 12, 2025Ipsen Biopharmaceuticals, Inc
May 12, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$1,377
Apr 30, 2025Intercept Pharmaceuticals, Inc.
Apr 30, 2025
Speaking at a medical education program
OCALIVA · Hepatology / Gastroenterology
$3,720
Apr 29, 2025Intercept Pharmaceuticals, Inc.
Apr 29, 2025
Speaking at a medical education program
OCALIVA · Hepatology / Gastroenterology
$3,720
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Consulting Fee
OCALIVA · Hepatology / Gastroenterology
$5,580
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$657
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$88.30
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$49.00
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL
$35.00
Mar 28, 2025Intercept Pharmaceuticals, Inc.
Mar 28, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$307
Mar 1, 2025Gilead Sciences, Inc.
Mar 1, 2025
Travel and Lodging
Epclusa · HCV · travel to Atlanta, GA · in-kind
Company’s description;4026685;GTF;10004544
$284
Feb 8, 2025Ipsen Biopharmaceuticals, Inc
Feb 8, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$1,836

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Kentucky →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $38,803 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Gilead Sciences, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in Louisville

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 14, 2017), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1629117312. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.